Split History
ETFs Holding CRIS »    CRIS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Curis is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Co.'s clinical stage drug candidates are: Emavusertib, which is being tested in a Phase 1/2 dose escalating clinical trial in patients with non-Hodgkin lymphomas; CI-8993, which is a monoclonal antibody; Fimepinostat, which is a small molecule that potently inhibits the activity of histone deacetylase, and phosphotidyl-inositol 3 kinase; CA-170, for which Co. has announced initial data from a clinical study in patients with mesothelioma in conjunction with the Society of lmmunotherapy of Cancer; and CA-327, which is a small molecule antagonist of PDL1 and TIM3. According to our CRIS split history records, Curis has had 1 split.
CRIS split history picture
Curis (CRIS) has 1 split in our CRIS split history database. The split for CRIS took place on May 30, 2018. This was a 1 for 5 reverse split, meaning for each 5 shares of CRIS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.

When a company such as Curis conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CRIS split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Curis shares, starting with a $10,000 purchase of CRIS, presented on a split-history-adjusted basis factoring in the complete CRIS split history. CRIS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/10/2012
End date: 12/06/2022
Start price/share: $15.70
End price/share: $0.76
Dividends collected/share: $0.00
Total return: -95.16%
Average Annual Total Return: -26.14%
Starting investment: $10,000.00
Ending investment: $483.97
Years: 9.99
Date Ratio
05/30/20181 for 5
CRIS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CRMD Split History
CRTX Split History
CRVL Split History
CRY Split History
CSBR Split History
CSII Split History
CSU Split History
CTIC Split History
CTRV Split History
CTRX Split History

Also explore: CRIS shares outstanding history

Email EnvelopeFree CRIS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Checkpoint Therapeutics, Inc. (CKPT)
UpHealth, Inc. (UPH)
MediWound Ltd. (MDWD)
Eloxx Pharmaceuticals, Inc. (ELOX)
Baudax Bio, Inc. (BXRX)
Petros Pharmaceuticals, Inc. (PTPI)
Tuesday Morning Corporation (TUEM)
DURECT Corporation (DRRX)
CNS Pharmaceuticals, Inc. (CNSP)
Astrotech Corporation (ASTC)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CRIS Insider Buying

CRIS Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.